Background: Allergic asthma is characterized by chronic inflammation and remod-
hyper-responsiveness (AHR), 1 provided by activated B cells. 7, 8 Fully differentiated T FH migrate into the B-cell follicle, further migrating into newly formed anatomical structures called germinal centres (GC). 6 Here, T FH form tight, cognate interactions with GC B cells, providing survival and differentiation signals to the B cells in return for T-cell receptor (TCR) signalling and co-stimulation. 2, 5, 7 The co-stimulatory molecule ICOS is required for T-cell activation and is upregulated on CD4 + T cells following TCR engagement. 9 Importantly, however, T FH uniquely require sustained ICOS/ICOS-L signalling throughout an immune response and after DC priming to maintain their phenotype, unlike other CD4 + T-cell subsets. 10 The role of T FH in allergic asthma appears to be complex. T FH are found in the SLOs of mice that have undergone sensitization and challenge with HDM [11] [12] [13] and are required for allergen-specific IgE production. 14, 15 T FH isolated from the lung draining lymph nodes can migrate to the lungs and become Th2 cells, enhancing allergic airway disease (AAD), when injected intravenously. 13 In con- 
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Chronic allergen exposure drives T follicular helper cell (TFH) formation in the lung draining lymph node after 1 week and the lung tissue after 3 weeks TFH at both sites interact with germinal centre B cells and are critical for the production of allergen specific IgE Allergic disease is also hallmarked by cellular inflammation and airway hyperresponsiveness driven by IL-13 Blocking ICOS and ICOS-L interactions between TFH and B cells reduces allergen specific IgE production and also dampens other hallmark symptoms of allergic airway disease Mice were culled at the end of week 5. All animals were harvested 18 hours after the final allergen dose.
| Flow cytometry assessment
Cell suspensions were acquired as previously described 18 and were stained in flow cytometry buffer (PBS containing 2% foetal calf serum and 2 mmol/L EDTA). To reduce nonspecific binding, cell suspensions were incubated with antibody cocktails containing anti-CD16/32 antibody. Cells were extracellularly stained in antibody cocktails for 30 minutes at 4°C, apart from stains containing CXCR5
which were incubated at room temperature in the dark for 1 hour.
For detection of intracellular cytokines, cells were incubated with 50 ng/mL phorbol myristate acetate, 500 ng/mL ionomycin and 10 μg/mL brefeldin A for 5 hours at 37°C and 5% CO 2 . Table S1 .
| Assessment of lung function
Airway hyper-responsiveness was measured in anesthetized and tracheotomized mice in response to increasing doses of methacholine (3-100 mg/mL; Sigma-Aldrich, MO, USA) using the flexiVent system (Scireq, Montreal, Canada) as previously described. 
| Cytokine analysis
IL-13, IL-17A and IL-21 were measured using Ready Set Go Kits (eBioscience, CA, USA), Eotaxin-2 using mouse CCL24/Eotaxin-2 DuoSet ELISA and IL-5 using paired antibodies (R&D systems, Abington, UK). All ELISAs were performed according to manufacturer's instructions. Statistical significance was determined using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001, n = 5 per time-point. Representative data from two independent experiments UWADIAE ET AL. were absent and comparable to PBS controls in the mLN and lungs after 1 week of aero-allergen inhalation (Figure 2A and B). However, after 3 weeks of HDM exposure, GC B-cell frequencies were significantly elevated in the mLN, lungs and spleen, remaining consistently raised between weeks 3 and 5. (Figure 2A , Figure S4 ). Similar results were observed following ALT exposure ( Figure S4 ).
| Statistical analysis
Allergen-specific antibodies, especially IgE, are a key feature of AAD. Allergen-specific IgE and IgG1 were detectable in allergenexposed mice from 3 weeks onward ( Figure 2C and D) . Sustained exposure to HDM did not further alter the levels of allergen-specific IgE ( Figure 2C ), but did increase IgG1 ( Figure 2D ). These data show chronic allergen exposure to generate local and systemic GC B-cell responses, alongside allergen-specific antibody which increase over time and are preceded by T FH responses.
| ICOS/ICOS-L interactions sustain T FH and GC B cells
T FH require sustained signalling via ICOS to maintain their phenotype Endpoint titres are displayed. C, HDM-specific IgE, D, HDMspecific IgG1. Statistical significance was determined using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001. n = 5 mice per time-point. Representative data from two independent experiments F I G U R E 3 ICOS/ICOS-L interactions are required to sustain T FH during chronic allergic airway disease (AAD). Adult female BALB/c mice were exposed (i.n) to 25 μg house dust mite (HDM) or 25 μL phosphate-buffered saline (PBS), three times a week for 5 weeks. all groups. E, Serum was titrated, and allergen-specific antibody was measured by ELISA. Endpoint titres are displayed for IgE and IgG1. Statistical significance was determined using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001. Data are pooled from two independent experiments, n = 8 for PBS-treated groups, n = 12 for HDM-treated groups successfully depleted using α-ICOS-L and this is associated with reduced GC B-cell responses, lung plasmablasts and allergen-specific IgE but not IgG1.
| α-ICOS-L treatment dampens lung inflammation and reduces AHR
Airway hyper-responsiveness and inflammation are key indicators of AAD progression. α-ICOS-L administration successfully reduced aeroallergen induced cellular infiltration into the lungs compared to IgGtreated controls ( Figure 4A ). The total number of lung eosinophils was reduced with allergen and α-ICOS-L co-administration ( Figure 4B) ; however, the proportion of lung eosinophils were unchanged ( Figure 4C) . A similar trend was observed during ALT-driven AAD ( Figure S8 ).
Allergen-treated mice showed increased AHR, with raised airway resistance and elastance, and reduced compliance compared to PBS controls in response to increasing doses of methacholine ( Figure 4D ). Treatment of HDM-exposed mice with α-ICOS-L resulted in reduced airway resistance and elastance and increased compliance, indicative of improved lung function compared to HDM-treated control mice ( Figure 4D ). This was also observed for ALT-induced AAD ( Figure S6 ). Despite this α-ICOS-L administration had no impact on HDM-induced goblet cell hyperplasia, collagen deposition or airway smooth muscle hyperplasia and hypertrophy ( Figure S9A-I) . Taken together the data shows that therapeutic administration of α-ICOS-L after disease establishment improved airway inflammation and lung function.
| α-ICOS-L reduces overall inflammation without specifically targeting Th2 cells or ILC2s
To determine the mechanism by which α-ICOS-L treatment could be impacting pulmonary inflammation and AHR, the release of F I G U R E 4 Therapeutic ICOS-L blockade improves chronic allergic airway disease. Adult female BALB/c mice were exposed (i.n) to 25 μg house dust mite (HDM) or 25 μL phosphate-buffered saline (PBS), three times a week for 5 weeks. From the start of week 4, mice were also administered 150 μg anti-ICOS-L (α-ICOS-L) or isotype control (IgG) antibody (i.p) three times a week. Mice were culled at the end of week 5. A, Number of lung cells, B, Lung eosinophil numbers, C, Proportions of lung eosinophils, D, Airway hyper-responsiveness was measured by exposing mice to 0-100 mg/mL methacholine (MCh) using the flexiVent system during HDM-induced allergic airway disease. Airway resistance, elastance and compliance were measured. Curves display mean±SEM. Statistical significance between HDM+ IgG and HDM+α-ICOS-L groups was determined using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001. Data are pooled from two independent experiments, n = 8 for PBS-treated groups, n = 12 for HDM-treated groups several important soluble mediators in the lungs was measured.
HDM-treated animals administered IgG displayed increased lung IL-13, IL-17A, IL-21, IL-5 and eotaxin-2 compared to PBS controls (Figure 5A-E). α-ICOS-L treatment reduced lung IL-13 and IL-17A
concentrations compared to IgG aeroallergen exposed mice (Figure 5A and B). IL-5 was reduced but did not reach significance, while no change was observed for Eotaxin-2 ( Figure 5D and E).
Interestingly, the T FH effector cytokine IL-21 was unchanged after
α-ICOS-L treatment ( Figure 5C ). T FH have been shown to accumulate and become dysregulated during sustained antigen exposure, 24 and to be capable of differentiating into Th2 cells after adoptive transfer. 13 Here, T FH were reduced together with both secreted IL-13 and IL-13 + CD4 + T cells, therefore the capacity of T FH to produce IL-13 was examined. Using IL-13 GFP reporter mice, CXCR5 expression was found to be separated from IL- 
Consistent with T FH reductions after ICOS-L blockade GC B cells
in the lungs and SLOs and lung plasmablasts are also reduced. Even after this relatively short intervention HDM-specific IgE, but not IgG1, also decline. IgE's half-life is short in comparison to other immunoglobulin isotypes 33 ; therefore, after serum transfer Der p1-and Lol p 1-specific IgE decline rapidly over a 50-day period while IgG remains stable. 34 Consequently, a more prolonged α−ICOS-L protocol may be required to sufficiently alter IgG1. 21 Nonetheless serum MCPT1, an important indicator of mast cell activation, 35 also decreases suggesting the observed IgE reduction to adequately F I G U R E 6 IL-13 + CD4 + T cells and ILCs are not directly targeted by ICOS-L blockade. A-B, Adult female BALB/c mice were exposed to either 25 μg house dust mite (HDM) or 25 μL phosphate-buffered saline (PBS), three times a week for up to 5 weeks. ). Statistical significance was determined using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001. Data are pooled from two independent experiments, n = 6 for PBS-treated groups, n = 12 for HDM-treated groups UWADIAE ET AL. 
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